Communiqués RVL Pharmaceuticals plc

Actions

RVLPQ

IE00BF2HDL56

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets Autres places de cotation 18:53:25 15/07/2026			Varia. 5j.	Varia. 1 janv.
0,000001 ^USD	0,00%		0,00%	-

01/05	Rvl Pharmaceuticals lance Upneeq Reveal Under Eye Complex	CI
08/05/24	Relief Therapeutics réorganise entièrement sa direction	AW

Communiqués

20/05/24	RVL Pharmaceuticals - Upneeq Wins 2024 Shape Skin Award, 'Best for Lift', in the Professional Treatment Category	AQ
12/10/23	RVL Pharmaceuticals plc Announces Prepackaged Reorganization of Certain U.S. Subsidiaries	AQ
25/08/23	RVL Pharmaceuticals : Regulation FD Disclosure - Form 8-K	PU
23/08/23	RVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment Conference	AQ
16/08/23	RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules	AQ
14/08/23	RVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business Review	AQ
02/08/23	RVL Pharmaceuticals plc to Discuss Second Quarter 2023 Financial Results and Provide Commercial Update	AQ
05/07/23	RVL Pharmaceuticals plc Provides Business Update	AQ
15/06/23	RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General Meeting	AQ
18/05/23	RVL Pharmaceuticals : 2022 Irish Statutory Financial Statements	PU
15/05/23	RVL Pharmaceuticals : Corporate Presentation May 2023	PU
11/05/23	RVL Pharmaceuticals plc Reports First Quarter 2023 Financial Results; Provides Commercial Update	AQ
04/05/23	RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial Update	AQ
12/04/23	RVL Pharmaceuticals : Corporate Presentation April 2023	PU
03/04/23	RVL Pharmaceuticals Announces that Upneeq® Wins “Best Eye Drop for Drooping Lids” NewBeauty in 13th Annual Beauty Awards	AQ
20/03/23	RVL PHARMACEUTICALS PLC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
20/03/23	RVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Commercial Update	AQ
15/03/23	RVL Pharmaceuticals plc to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Commercial Update	AQ
10/03/23	RVL PHARMACEUTICALS PLC : Regulation FD Disclosure (form 8-K)	AQ
09/01/23	RVL Pharmaceuticals plc Announces Preliminary Fourth Quarter Sequential Growth of 21% and Full Year 2022 UPNEEQ® Net Product Sales	AQ
01/12/22	RVL Pharmaceuticals plc to Present at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference	AQ
30/11/22	RVL Pharmaceuticals : Corporate Presentation November 2022	PU
10/11/22	RVL PHARMACEUTICALS PLC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
10/11/22	RVL Pharmaceuticals plc Reports Third Quarter 2022 Financial Results; Provides Commercial Update	AQ
03/11/22	RVL Pharmaceuticals plc to Discuss Third Quarter 2022 Financial Results and Provide Commercial Update	AQ